Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2023 Jun 6.
Published in final edited form as: Am J Ophthalmol. 2022 Feb 25;240:51–57. doi: 10.1016/j.ajo.2022.02.016

The blue-light-hazard vs. blue-light-hype

Martin A Mainster 1, Oliver Findl 2, H Burkhard Dick 3, Thomas Desmettre 4, Gerardo Ledesma-Gil 5, Christine A Curcio 6, Patricia L Turner 1
PMCID: PMC10243475  NIHMSID: NIHMS1901654  PMID: 35227699

Abstract

PURPOSE:

The blue-light-hazard is the experimental finding that blue light is highly toxic to the retina (photic retinopathy), in brief abnormally intense exposures, including sungazing or vitreoretinal endoillumination. This term has been misused commercially to suggest, falsely, that ambient environmental light exposure causes phototoxicity to the retina, leading to age-related macular degeneration (AMD). We analyze clinical, epidemiological and biophysical data regarding blue-filtering optical chromophores.

DESIGN:

Multi-institutional perspective.

METHODS:

Analysis and integration of data regarding the blue-light-hazard and blue-blocking filters in ophthalmology and related disciplines.

RESULTS:

Large epidemiological studies show that blue-blocking intraocular lenses (IOLs) do not decrease AMD risk or progression. Blue-filtering lenses cannot reduce disability glare because image and glare illumination are decreased in the same proportion. Blue light essential for optimal rod and retinal ganglion photoreception is decreased by progressive age-related crystalline lens yellowing, pupillary miosis and rod and retinal ganglion photoreceptor degeneration. Healthful daily environmental blue light exposure decreases in older adults, especially women. Blue light is important in dim environments where inadequate illumination increases risk of falls and associated morbidities.

CONCLUSIONS:

The blue-light-hazard is misused as a marketing stratagem to alarm people into using spectacles and IOLs that restrict blue light. Blue light loss is permanent for pseudophakes with blue-blocking IOLs. Blue-light-hazard misrepresentation flourishes despite absence of proof that environmental light exposure or cataract surgery causes AMD or that IOL chromophores provide clinical protection. Blue-filtering chromophores suppress blue light critical for good mental and physical health and for optimal scotopic and mesopic vision.

Keywords: Age-related macular degeneration, aging, all-cause-mortality, blue-blocking, blue-filtering, blue light, blue-light-hazard, chromophore, circadian, cognition, depression, disability glare, discomfort glare, headlight glare, intraocular lens, intraocular straylight, mesopic, nighttime driving, photic retinopathy, photoreception, photoxicity-AMD hypothesis, retinal ganglion photoreceptor, retinal phototoxicity, scotopic, sleep, sunglasses, ultraviolet

Table of contents statement:

The blue-light-hazard is the experimental finding that brief, abnormally-intense blue light is more phototoxic to retina than longer wavelengths. Blue light is critical for circadian photoreception essential for good health and for dim-light vision. Epidemiological studies show that AMD incidence and progression are unaffected by blue-blocking IOLs. The blue-light-hazard has been used as a marketing stratagem to alarm people into using blue-light-limiting spectacles and IOLs. Blue-light loss is permanent for pseudophakes with blue-filtering IOLs.


Few patients or clinicians who hear about the blue-light-hazard know what the term means. Major health care organizations warn patients to “safeguard your eyes from harmful blue light.”1 Articles in professional magazines caution that the “sun is your worst enemy,”2 claiming that sunlight “is a risk factor for age-related macular degeneration” (AMD).2 Large manufacturers assert that their products provide “protection against harmful blue light,”3, 4 claiming that “a pedestrian can encounter toxic blue light levels on a sunny summer day.”5 Some fearful patients retreat to unhealthful indoor lifestyles with increased risk of insomnia, depression and reduced longevity.6

Manufacturers have devoted vast resources to creating a commercially-expedient fear of blue light to market optical filters that reduce blue light transmission. These yellow-tinted blue-blocking (also known as “blue-filtering”) lenses decrease violet (400-440 nm) and blue (440-500 nm) wavelengths that are essential for dim environment vision, circadian photoreception and good health.68 When blue-blocking chromophores are used in intraocular lenses (IOLs), light restriction is permanent.9 Manufacturers cannot produce conventional lenses that improve vision by amplifying light so some choose to suppress useful light with colored chromophores, relying instead on marketing to convince people to pay more for “premium” products that provide less light for photoreception.

Decades of research have failed to provide conclusive evidence that environmental light exposure8, 10 or cataract surgery11, 12 increase the incidence or progression of AMD. There is strong and growing scientific evidence, however, that blue light is critical for dim environment vision and circadian photoreception, especially in aging eyes.68 Indeed, studies have shown that in comparison to yellow-tinted blue-blocking IOLs, colorless UV-blocking IOLs are associated with reduced depression13 and improved slow-wave sleep, cognition14 and even longevity.15 Additionally, blue-blocking IOLs decrease dim-light photoreception,8, 1619 and in some cases increase intraocular straylight20 which is the cause of disability glare, 21 i.e., loss of retinal image contrast.

Large epidemiological studies show that blue-filtering IOLs have no advantage over UV-blocking IOLs in reducing the incidence, progression or severity of AMD,2224 as predicted by earlier biophysical hazards analyses.8, 19 This perspective examines some of the myths and misperceptions used to promote blue-light-fright in consumers and clinical practice.

Normal environments do not pose a blue-light-hazard

The term blue-light-hazard describes an experimental finding that short wavelength light is more phototoxic to the retina than longer wavelengths when delivered in brief, intense, exposures.8, 19, 25 The phenomenon could have been called the ultraviolet-radiation-hazard because ultraviolet (UV) radiation in aphakic eyes is potentially more phototoxic than violet light which in turn is potentially more hazardous acutely than blue or longer wavelengths.26

Blue-light-hazard data originated from experiments on anesthetized rhesus monkeys using a 2500-watt xenon lamp and retinal exposures ranging from 1 to 1000 sec in duration.26 It has nothing to do with ordinary indoor or ambient outdoor lighting which produce retinal irradiances that are a million times lower in magnitude.8, 19, 25, 27 The blue-light-hazard refers only to exposures from brilliant light sources that can cause acute chorioretinal injuries such as solar, welder’s and operating microscope maculopathies.8, 19, 25 Misrepresentation of this term recently prompted the International Commission on Illumination to issue a position-statement emphasizing that the term blue-light-hazard should be used only for conditions involving staring at brilliant light sources such as the sun or welding arcs.25

The century-old phototoxicity-AMD hypothesis is unproven

Some manufacturers use the unproven phototoxicity-AMD hypothesis to justify blue-blocking chromophores. This hypothesis was proposed in 1975 based on histopathologic similarities between acute solar retinopathy and AMD.28 It conjectures that hypothetical cumulative retinal damage from repetitive acute environmental retinal phototoxicity (also known as photic retinopathy) may increase the risk of AMD. A similar conjecture was proposed in 1920 based on cataract-AMD incidence correlations that were later proven erroneous.29

The phototoxicity-AMD hypothesis was first applied to intraocular lenses (IOLs) in 1978.30 It was shown that IOLs in use then transmitted visually-unnecessary and potentially harmful UV radiation that could be blocked fully with IOL chromophores.30 UV-absorbing IOL chromophores were incorporated into IOLs shortly thereafter but their protective value remains unproven.31 Indeed, some IOLs marketed as “premium” because of their accommodative properties did not incorporate UV-absorbing chromophores for many years.32

The potential role of cumulative environmental light exposure in the pathogenesis of AMD remains unproven despite decades of intensive investigation. Most major epidemiological studies found no association between light exposure and AMD.8, 9 A recent meta-analysis of 14 previous studies involving over 40,000 people also found no association between AMD risk and sunlight exposure.10 The Centers for Medicare and Medicaid Services concluded that the “relationship between blue light and macular degeneration is speculative and not proven by available evidence.”32, 33 Fourteen years later, the International Commission on Illumination published the same conclusion.25

RPE cell cultures are not valid models of clinical AMD

Retinal phototoxicity experiments involving RPE cell cultures are used to suggest that blue-blocking IOL and spectacle chromophores can decrease AMD. Retinal phototoxicity is a useful technique for studying perturbations of retinal pigment epithelium (RPE) physiology if the cells exhibit characteristic properties of confluence, polarity, and barrier function. It requires high retinal irradiances that overwhelm RPE monolayer repair mechanisms acutely, especially when cells have been incubated with a photosensitizer.8 Some investigators have used a blue-blocking filter to reduce experimental blue light irradiance in phototoxicity experiments, predicably decreasing cell culture damage.8, 9, 32 The experiments are then said to support the “efficacy”34 or “protection”35 of blue-blocking IOLs.34, 35

An important development in the last 15 years is improved understanding of how AMD does proceed, using data from human eye pathology, genetics, gene expression profiling, clinical imaging and epidemiology, among other approaches.36, 37 Additionally, there are well-supported biologically-defensible actions for patients to slow AMD progression including smoking cessation and dietary modification.3840 Knowledge gaps remain but studies collectively implicate pathways of complement, lipid transfer, and extracellular matrix remodeling that reflect the biology of cone- and rod-specific support systems and sequelae of inflammation, in a vasculogenic disease not dependent on retinal phototoxicity.36, 37, 41 The A2E bisretinoid compound used as a photosensitizer in many in vitro light damage studies has been repeatedly shown to be lower in human macula than in the periphery, raising questions about its role in macular disease.42

RPE cell culture experiments have been described in recent manufacturer-supported studies as an “in vitro model of AMD.”5 Conversely, more than a decade of anti-vascular endothelial growth factor therapy monitored by optical coherence tomography has demonstrated that AMD pathophysiology is multilayer and only partly represented by a single cell layer, even an important one such as the RPE.36, 41 Additionally, lifelong aging cannot be simulated by acute injury.8, 9, 32 Acute phototoxicity can damage the macula but cannot simulate a lifetime of normal environmental light exposure just as scalding water can scar skin but cannot simulate a lifetime of normal bathing.9 Intense blue light is harmful to non-physiologic RPE cell cultures but ordinary environmental light exposure has not been proven to be harmful to normal human retinas.

Yellow chromophores cannot decrease disability glare

Clinical disability glare occurs when intraocular light scattering (straylight) reduces the contrast of retinal images.21 In common real-world situations, retinal targets are illuminated by light sources (e.g., the sun) with a spectrum similar to the glare source (e.g., the sun). Blue-blocking filters decrease image and glare illumination in exactly the same proportion so they cannot affect retinal image contrast or reduce disability glare.21 A recent study found that blue-blocking IOLs increase straylight,20 the cause of disability glare, an effect probably caused by glistenings rather than light filtering.21 Sunglasses are useful for reducing discomfort glare but blue-blocking IOLs are not effective substitutes for sunglasses.21

Psychophysical tests can be biased to show that blue-blocking filters decrease artificial glare by using laboratory glare sources that are bluer than target illumination.21, 43 In one manufacturer-supported study, the spectrum of the blue-weighted glare source was labeled falsely as the redder target illumination spectrum21, 43 and contrast testing was performed on a violet-blue background. The Centers for Medicare and Medicaid Services twice concluded that product-biased experiments fail to demonstrate that blue-filtering IOLs produce “clinically meaningful, improved outcomes” in “driving safety under glare conditions.”44 A recent independent scientific study documented that blue-blocking spectacles do not improve pedestrian detection or reduce headlight glare in nighttime driving situations.45

Blue light is important for rod photoreception

Colorless UV-blocking and yellow-tinted blue-blocking IOLs are seldom implanted in contralateral eyes because blue-filtering chromophores can produce a noticeable yellowish cast even in photopic viewing situations.46 This imbalance occurs because yellow IOL chromophores block 67-83% of violet and 27-40% of pseudophakic blue light, depending on their dioptric power.8, 19 In bright conditions, more retinal illuminance is available than needed for cone photoreceptors so blue-blocking filters don’t affect performance adversely on standard photopic tests such as visual acuity, contrast sensitivity or color vision.47 Some tests have shown, however, that colorless UV-blocking IOLs provide photopic luminance contrast and color discrimination superior to yellow-tinted blue-filtering IOLs.48, 49 For example, pseudophakic differentiation of navy from black clothing is significantly better with colorless lenses.50

Violet and blue light provide 45% of aphakic rod-mediated scotopic sensitivity but only 7% of photopic sensitivity. Rod-mediated vision including scotopic and mesopic sensitivity declines with aging because of crystalline lens yellowing,51 progressive pupillary miosis,52 selective loss of macular rods before cones, and slowed rod-mediated dark adaptation due to impairment of retinoid recycling.53 Cataract surgery increases blue light available for rod photoreception, regardless of IOL spectral transmittance. In dim environments when retinal illuminance is marginal, however, older pseudophakes benefit from having as much blue light reception as possible.9, 54 Yellow IOL chromophores decrease available blue light, permanently.8, 17, 19, 5456

Mesopic vision is decreased in patients with yellow-tinted blue-blocking compared to colorless UV-blocking IOLs,17, 18 supporting prior biophysical analyses showing that blue-blocking IOLs reduce rod-mediated vision.19, 56, 57 Blue-blocking IOLs also decrease scotopic vision at violet and blue wavelengths.55 Reduced rod-mediated dim-environment vision is correlated with an increased risk of falling and its resultant serious morbidities as well as with nighttime driving problems.5860

Blue light is critical for retinal ganglion photoreception

Blue light sensitive retinal ganglion photoreceptors profoundly influence mental and physical health.6, 7, 61, 62 Only about 1% of retinal ganglion cells are photoreceptive and express the blue light sensitive photopigment melanopsin.63 Their primary function is to monitor environmental light levels and send this information to the suprachiasmatic nuclei to synchronize the human body’s circadian clock.6, 7, 61, 62 They require high retinal illuminances well above typical indoor illumination levels.6 The maximal sensitivity for human retinal ganglion photoreceptors is 460 nm,62, 64, 65 in the middle of the blue part of the spectrum.

Bright, well-timed blue light exposure is needed for effective suprachiasmatic nuclei circadian control and optimal neurobiologic health. Insufficient exposure dampens hormonal and physiological signaling, reducing physical and psychological health and contributing to sleep problems, depression and the risk of all-cause mortality.6, 61, 6668 Daily bright light exposure declines markedly in elderly adults, with women averaging half that of men.6 Institutionalized Alzheimer’s patients may receive fewer than 10 minutes of daily light exceeding 1000 lux.6 Morbidity from environmental light deficiency is reversable with effective environmental light exposure shown to be beneficial for insomnia, depression, cognition and degenerative disorders including Alzheimer’s disease.6, 61 Light exposures from artificial devices such as computer monitors and cell phones can disrupt circadian rhythms but there’s no evidence they can cause retinal damage or AMD.69, 70

Retinal ganglion photoreceptor function is diminished by progressive age-related ocular changes including crystalline lens yellowing,7 pupillary miosis8 and retinal ganglion cell degeneration. Cataract surgery cannot reverse age-related pupillary miosis or retinal ganglion cell loss but it can compensate for crystalline lens yellowing and increase blue light transmission to optimize the function of the remaining retinal ganglion and rod photoreceptors.68 Retinal ganglion degeneration is accelerated in neurodegenerative disorders including Parkinson’s and Alzheimer’s diseases, glaucoma and diabetic retinopathy,62 which all potentially benefit from the additional blue light available after cataract surgery.

It is difficult to perform studies that directly compare the circadian effects of colorless UV-blocking vs. yellow-tinted blue-blocking IOLs because numerous factors must be controlled including individual daily outdoor light exposure and sleep habits. Nonetheless, most circadian-related studies show either (1) no advantage for yellow-tinted blue-blocking IOLs71, 72 or (2) advantages for colorless UV-blocking IOLs vs. yellow-tinted blue-blocking ones in functions including cognitive performance14, sleep14, 73, 74 and depression.13 Additionally, a 15-year-long cohort study showed that colorless UV-blocking IOLs in comparison to yellow-tinted blue-filtering ones were associated with a significantly reduced risk of all-cause mortality.15

Summary

Photic retinopathy from intense light is sometimes referred to as a blue-light-hazard because shorter, bluer wavelengths are more acutely phototoxic, experimentally, than longer ones.8, 25 Ordinary ambient environmental light exposure does not cause this injury. The hazard has been used as a marketing ploy to alarm consumers and clinicians into using lenses that restrict blue light.8 People are encouraged to pay more for less light, motivated by misleading advertisements and the affirmations of professional “thought-leaders” that blue-filtering may protect them from AMD.9, 32 This blue light marketing stratagem persists despite: (1) the absence of scientific proof that sunlight or cataract surgery causes AMD8, 10 or that blue-filtering IOLs reduce the risk of AMD, 2224, 75 (2) accumulating evidence that blue light is essential for good mental and physical health6, 61, 62 as well as for optimal scotopic and mesopic vision.8, 16, 17, 54 and (3) scientific evidence that AMD pathophysiology involves major biological processes in the photoreceptor support system that does not require light damage as an explanation.36, 37, 41

Pseudophakes with colorless IOLs are free to choose any outdoor sunglass filter they wish and still have optimal mesopic, scotopic and circadian photoreception.8 Pseudophakes lose this freedom of photoreception when manufacturers incorporate ever-present blue-blocking filters into their IOLs. Blue-filtering IOL pseudophakes usually achieve improved photopic vision after cataract surgery. Most are unaware that blue light valuable for declining populations of rods and retinal ganglion cells has been restricted, permanently.8

Acknowledgments:

We thank many authors for contributions that we could not cite due to journal policy for Perspective publications. We direct readers to prior comprehensive reviews by authors MAM and PLT.

Disclosure statement:

Martin A. Mainster is a consultant for Ocular Instruments, Inc. Oliver Findl is a scientific advisor to Alcon, Carl Zeiss Meditec, Croma, Johnson & Johnson and Merck. Christine A. Curcio receives research support from Genentech/ Hoffman LaRoche and Regeneron and is a stockholder in MacRegen Inc. Fundamental research in autofluorescence imaging was supported by NIH grants R01EY06019 and R01EY027948 (to CAC). H. Burkard Dick, Gerardo Ledesma-Gil, Thomas Desmettre, and Patricia L. Turner have no commercial interests.

References

  • 1.Pierce B, True D. Protect your eyes from harmful blue light. Speaking of Health, Mayo Clinic Health Care System. https://www.mayoclinichealthsystem.org/hometown-health/speaking-of-health/protect-your-eyes-from-harmful-light, accessed 9 April 2021: 14 September 2020.
  • 2.Rosenfield M. Living with blue light exposure: the sun is your worst enemy, and digital devices aren’t as bad as you think. Rev Optom 2019;156:56–60. [Google Scholar]
  • 3.Baillet G, Granger B. How Transitions (R) lenses filter harmful blue light. Int Rev Ophthalmic Optics, Points De Vue, March, http://www.pointsdevue.com/article/how-transitionsr-lenses-filter-harmful-blue-light, accessed 8 April 2021: March 2016. [Google Scholar]
  • 4.Essilor-International-SAS. Harmful blue light: Innovative solutions for all. Essilor. https://www.essilor.com/en/medias/news/harmful-blue-light-innovative-solutions-for-all/, accessed 9 April 2021: 12 February, 2019. [Google Scholar]
  • 5.Marie M, Forster V, Fouquet S, et al. Phototoxic damage to cone photoreceptors can be independent of the visual pigment: the porphyrin hypothesis. Cell Death Dis 2020;11:711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Turner PL, Van Someren EJW, Mainster MA. The role of environmental light in sleep and health: Effects of ocular aging and cataract surgery. Sleep Med Rev 2010;14:269–80. [DOI] [PubMed] [Google Scholar]
  • 7.Turner PL, Mainster MA. Circadian photoreception: ageing and the eye’s important role in systemic health. Br J Ophthalmol 2008;92:1439–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Mainster MA, Turner PL. Blue-blocking IOLs decrease photoreception without providing significant photoprotection. Surv Ophthalmol 2010;55:272–89. [DOI] [PubMed] [Google Scholar]
  • 9.Mainster MA, Turner PL. Blue-Blocking IOLs vs. Short-Wavelength Visible Light: Hypothesis-Based vs. Evidence-Based Medical Practice. Ophthalmology 2011;118:1–2. [DOI] [PubMed] [Google Scholar]
  • 10.Zhou H, Zhang H, Yu A, Xie J. Association between sunlight exposure and risk of age-related macular degeneration: a meta-analysis. BMC Ophthalmol 2018;18:331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Age-Related Eye Disease Study 2 Research G, Huynh N, Nicholson BP, et al. Visual acuity after cataract surgery in patients with age-related macular degeneration: age-related eye disease study 2 report number 5. Ophthalmology 2014;121:1229–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Rim TH, Lee CS, Lee SC, Kim S, Kim SS, Epidemiologic Survey Committee Of The Korean Ophthalmological S. Association between Previous Cataract Surgery and Age-Related Macular Degeneration. Seminars in ophthalmology 2017;32:466–473. [DOI] [PubMed] [Google Scholar]
  • 13.Mendoza-Mendieta ME, Lorenzo-Mejia AA. Associated depression in pseudophakic patients with intraocular lens with and without chromophore. Clin Ophthalmol 2016;10:577–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Chellappa SL, Bromundt V, Frey S, et al. Association of Intraocular Cataract Lens Replacement With Circadian Rhythms, Cognitive Function, and Sleep in Older Adults. JAMA Ophthalmol 2019;137:878–85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Griepentrog JE, Zhang X, Marroquin OC, et al. Association between conventional or blue-light-filtering intraocular lenses and survival in bilateral cataract surgery patients. iScience 2021;24:102009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Vicente EG, Arranz I, Galarreta D, et al. Effect of different spectral power distributions on mesopic visual performance with blue light-filtering intraocular lens. LEUKOS 2021;17:59–74. [Google Scholar]
  • 17.Wirtitsch MG, Schmidinger G, Prskavec M, et al. Influence of blue-light-filtering intraocular lenses on color perception and contrast acuity. Ophthalmology 2009;116:39–45. [DOI] [PubMed] [Google Scholar]
  • 18.Wang H, Wang J, Fan W, Wang W. Comparison of photochromic, yellow, and clear intraocular lenses in human eyes under photopic and mesopic lighting conditions. J Cataract Refract Surg 2010;36:2080–6. [DOI] [PubMed] [Google Scholar]
  • 19.Mainster MA. Violet and blue light blocking intraocular lenses: photoprotection versus photoreception. Br J Ophthalmol 2006;90:784–92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.van Os A, Stassen MJC, Tassignon MJ, Rozema JJ. Influence of yellow filters on straylight measurements. J Cataract Refract Surg 2017;43:1077–1080. [DOI] [PubMed] [Google Scholar]
  • 21.Mainster MA, Turner PL. Glare’s causes, consequences, and clinical challenges after a century of ophthalmic study. Am J Ophthalmol 2012;153:587–93. [DOI] [PubMed] [Google Scholar]
  • 22.Achiron A, Elbaz U, Hecht I, et al. The Effect of Blue-Light Filtering Intraocular Lenses on the Development and Progression of Neovascular Age-Related Macular Degeneration. Ophthalmology 2021;128:410–416. [DOI] [PubMed] [Google Scholar]
  • 23.Hamel T, Rheault J, Simonyan D, Bourgault S, Rochette PJ. The Influence of Blue-Filtering Intraocular Lenses Implant on Exudative Age-Related Macular Degeneration: A Case-Control Study. Clin Ophthalmol 2021;15:2287–2292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Lee JS, Li PR, Hou CH, Lin KK, Kuo CF, See LC. Effect of blue light-filtering intraocular lenses on age-related macular degeneration: A nationwide cohort study with 10-year follow-up. Am J Ophthalmol 2021. [DOI] [PubMed] [Google Scholar]
  • 25.International-Commission-on-Illumination. CIE Position on the Blue Light Hazard. Commission Internationale de l’Eclairage, April, https://cie.co.at/publications/position-statement-blue-light-hazard-april-23-2019, accessed 9 April 2021: 23 April 2019. [Google Scholar]
  • 26.Ham WT Jr., Mueller HA, Ruffolo JJ Jr., Guerry D 3rd, Guerry RK. Action spectrum for retinal injury from near-ultraviolet radiation in the aphakic monkey. Am J Ophthalmol 1982;93:299–306. [DOI] [PubMed] [Google Scholar]
  • 27.Sliney DH, Wolbarsht ML. Safety with Lasers and Other Optical Sources: A Comprehensive Handbook. New York: Plenum Press, 1980:1035. [Google Scholar]
  • 28.Ts’o MOM, La Piana FG, Appleton B. The human fovea after sungazing. Trans Am Acad Ophthalmol Otolaryngol 1974;78:OP-677. [PubMed] [Google Scholar]
  • 29.van der Hoeve J Eye lesions produced by light rich in ultraviolet rays: senile cataract, senile degeneration of the macula. Am J Ophthalmol 1920;3:178–94. [Google Scholar]
  • 30.Mainster MA. Spectral transmittance of intraocular lenses and retinal damage from intense light sources. Am J Ophthalmol 1978;85:167–70. [DOI] [PubMed] [Google Scholar]
  • 31.Mainster MA. The spectra, classification, and rationale of ultraviolet-protective intraocular lenses. Am J Ophthalmol 1986;102:727–32. [DOI] [PubMed] [Google Scholar]
  • 32.Mainster MA, Turner PL. Blue-blocking intraocular lenses: myth or reality? Am J Ophthalmol 2009;147:8–10. [DOI] [PubMed] [Google Scholar]
  • 33.Centers-for-Medicare-&-Medicaid-Services. Medicare program: disapproval of adjustment in payment amounts for new technology intraocular lenses furnished by ambulatory surgical centers. Federal Register 2005;70:15337–15340. [Google Scholar]
  • 34.Marshall J. Filter and don’t get the blues. Cataract & Refractive Surgery Today Europe 2007;2:59–63. [Google Scholar]
  • 35.Kernt M, Walch A, Neubauer AS, et al. Filtering blue light reduces light-induced oxidative stress, senescence and accumulation of extracellular matrix proteins in human retinal pigment epithelium cells. Clin Exp Ophthalmol 2012;40:e87–97. [DOI] [PubMed] [Google Scholar]
  • 36.Curcio CA. Soft Drusen in Age-Related Macular Degeneration: Biology and Targeting Via the Oil Spill Strategies. Invest Ophthalmol Vis Sci 2018;59:AMD160–AMD181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Fleckenstein M, Keenan TDL, Guymer RH, et al. Age-related macular degeneration. Nat Rev Dis Primers 2021;7:31. [DOI] [PubMed] [Google Scholar]
  • 38.Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 2001;108:697–704. [DOI] [PubMed] [Google Scholar]
  • 39.Age-Related Eye Disease Study 2 Research G. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309:2005–15. [DOI] [PubMed] [Google Scholar]
  • 40.Merle BMJ, Colijn JM, Cougnard-Gregoire A, et al. Mediterranean Diet and Incidence of Advanced Age-Related Macular Degeneration: The EYE-RISK Consortium. Ophthalmology 2019;126:381–390. [DOI] [PubMed] [Google Scholar]
  • 41.Chen L, Messinger JD, Zhang Y, Spaide RF, Freund KB, Curcio CA. Subretinal drusenoid deposit in age-related macular degeneration: histologic insights into initiation, progression to atrophy, and imaging. Retina 2020;40:618–631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Quinn N, Csincsik L, Flynn E, et al. Comment and response to the article “The clinical relevance of visualizing the peripheral retina”by Nicola Quinn, Lajos Csincsik, Erin Flynn, Christine A. Curcio, Szilard Kiss, SriniVas R. Sadda, Ruth Hogg, Tunde Peto & Imre Lengyel. Prog Retin Eye Res 2021;83:100939. [DOI] [PubMed] [Google Scholar]
  • 43.Hammond BR, Renzi LM, Sachak S, Brint SF. Contralateral comparison of blue-filtering and non-blue-filtering intraocular lenses: glare disability, heterochromatic contrast, and photostress recovery. Clin Ophthalmol 2010;4:1465–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Centers-for-Medicare-&-Medicaid-Services. Final rule with comment period, CMS-1525-FC, RIN 0938-AQ26: blue-light filtering IOLs lack clinically meaningful improved outcomes. Federal Register 2011;76:74431–7. [Google Scholar]
  • 45.Hwang AD, Tuccar-Burak M, Peli E. Comparison of Pedestrian Detection With and Without Yellow-Lens Glasses During Simulated Night Driving With and Without Headlight Glare. JAMA Ophthalmol 2019;137:1147–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Olson MD, Miller KM. Implanting a clear intraocular lens in one eye and a yellow lens in the other eye: a case series. Am J Ophthalmol 2006;141:957–8. [DOI] [PubMed] [Google Scholar]
  • 47.Lavric A, Pompe MT. Do blue-light filtering intraocular lenses affect visual function? Optom Vis Sci 2014;91:1348–54. [DOI] [PubMed] [Google Scholar]
  • 48.Pierre A, Wittich W, Faubert J, Overbury O. Luminance contrast with clear and yellow-tinted intraocular lenses. J Cataract Refract Surg 2007;33:1248–52. [DOI] [PubMed] [Google Scholar]
  • 49.Schmack I, Schimpf M, Stolzenberg A, Conrad-Hengerer I, Hengerer FH, Dick HB. Visual quality assessment in patients with orange-tinted blue light-filtering and clear ultraviolet light-filtering intraocular lenses. J Cataract Refract Surg 2012;38:823–32. [DOI] [PubMed] [Google Scholar]
  • 50.Kiser AK, Deschler EK, Dagnelie G. Visual function and performance with blue-light blocking filters in age-related macular degeneration. Clin Experiment Ophthalmol 2008;36:514–20. [DOI] [PubMed] [Google Scholar]
  • 51.Barker FM, Brainard GC. The Direct Spectral Transmittance of the Excised Human Lens as a Function of Age, (FDA 785345 0090 RA). Washington, DC.: U.S. Food and Drug Administration, 1991. [Google Scholar]
  • 52.Yang Y, Thompson K, Burns SA. Pupil location under mesopic, photopic, and pharmacologically dilated conditions. Invest Ophthalmol Vis Sci 2002;43:2508–12. [PMC free article] [PubMed] [Google Scholar]
  • 53.Curcio CA, Owsley C. Rod-Mediated Dark Adaptation as a Suitable Outcome for Early and Intermediate Age-Related Macular Degeneration. Ophthalmology 2019;126:866–867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Li X, Kelly D, Nolan JM, Dennison JL, Beatty S. The evidence informing the surgeon’s selection of intraocular lens on the basis of light transmittance properties. Eye (Lond) 2017;31:258–272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Jackson GR. Pilot study on the effect of a blue-light-blocking IOL on rod-mediated (scotopic) vision. American Society for Cataract and Refractive Surgery, Washington DC, 2005 Annual Meeting, April 15-20, 2005. Washington, DC, USA, 2005. [Google Scholar]
  • 56.Artigas JM, Felipe A, Navea A, Artigas C, Garcia-Domene MC. Spectral transmittance of intraocular lenses under natural and artificial illumination: criteria analysis for choosing a suitable filter. Ophthalmology 2011;118:3–8. [DOI] [PubMed] [Google Scholar]
  • 57.Mainster MA, Sparrow JR. How much blue light should an IOL transmit? Br J Ophthalmol 2003;87:1523–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.McMurdo ME, Gaskell A. Dark adaptation and falls in the elderly. Gerontology 1991;37:221–4. [DOI] [PubMed] [Google Scholar]
  • 59.Sivak M, Olson PL, Pastalan LA. Effect of driver’s age on nighttime legibility of highway signs. Hum Factors 1981;23:59–64. [DOI] [PubMed] [Google Scholar]
  • 60.Scilley K, Jackson GR, Cideciyan AV, Maguire MG, Jacobson SG, Owsley C. Early age-related maculopathy and self-reported visual difficulty in daily life. Ophthalmology 2002;109:1235–42. [DOI] [PubMed] [Google Scholar]
  • 61.Turner PL, Mainster MA. Cataract surgery can improve health as well as vision. Ophthalmol Management (wwwophthalmologymanagementcom/issues/2011/march-2011/cataract-surgery-improves-overall-quality-of-life) 2011;15:44–50. [Google Scholar]
  • 62.Mure LS. Intrinsically Photosensitive Retinal Ganglion Cells of the Human Retina. Front Neurol 2021;12:636330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Kim US, Mahroo OA, Mollon JD, Yu-Wai-Man P. Retinal Ganglion Cells-Diversity of Cell Types and Clinical Relevance. Front Neurol 2021;12:661938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Mainster MA. Blue-blocking intraocular lenses and pseudophakic scotopic sensitivity. J Cataract Refract Surg 2006;32:1403–4. [DOI] [PubMed] [Google Scholar]
  • 65.Thapan K, Arendt J, Skene DJ. An action spectrum for melatonin suppression: evidence for a novel non-rod, non-cone photoreceptor system in humans. J Physiol 2001;535:261–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 2003;4:649–61. [DOI] [PubMed] [Google Scholar]
  • 67.Patel D, Steinberg J, Patel P. Insomnia in the Elderly: A Review. J Clin Sleep Med 2018;14:1017–1024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Robbins R, Weaver MD, Barger LK, Wang W, Quan SF, Czeisler CA. Sleep difficulties, incident dementia and all-cause mortality among older adults across 8 years: Findings from the National Health and Aging Trends Study. J Sleep Res 2021:e13395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Clark AJ, Yang P, Khaderi KR, Moshfeghi AA. Ocular Tolerance of Contemporary Electronic Display Devices. Ophthalmic surgery, lasers & imaging retina 2018;49:346–354. [DOI] [PubMed] [Google Scholar]
  • 70.O’Hagan JB, Khazova M, Price LL. Low-energy light bulbs, computers, tablets and the blue light hazard. Eye (Lond) 2016;30:230–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Alexander I, Cuthbertson FM, Ratnarajan G, et al. Impact of cataract surgery on sleep in patients receiving either ultraviolet-blocking or blue-filtering intraocular lens implants. Invest Ophthalmol Vis Sci 2014;55:4999–5004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Nishi T, Saeki K, Miyata K, et al. Effects of Cataract Surgery on Melatonin Secretion in Adults 60 Years and Older: A Randomized Clinical Trial. JAMA Ophthalmol 2020;138:405–411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Ayaki M, Negishi K, Suzukamo Y, Tsubota K. Color of intra-ocular lens and cataract type are prognostic determinants of health indices after visual and photoreceptive restoration by surgery. Rejuvenation Res 2015;18:145–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Lee TM, Loh EW, Kuo TC, Tam KW, Lee HC, Wu D. Effects of ultraviolet and blue-light filtering on sleep: a meta-analysis of controlled trials and studies on cataract patients. Eye (Lond) 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Downie LE, Wormald R, Evans J, et al. Analysis of a Systematic Review About Blue Light-Filtering Intraocular Lenses for Retinal Protection: Understanding the Limitations of the Evidence. JAMA Ophthalmol 2019;137:694–7. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES